Plain-English translation of NCT05908084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares two different ways to create a blood vessel access for dialysis in women with end-stage kidney disease. You would receive either the Humacyte —a lab-grown blood vessel—or a traditional arteriovenous fistula (AVF), which is created by connecting an artery directly to a vein. Researchers want to see which option works better and is safer over one year.
Women with kidney failure need reliable access to their blood vessels for dialysis treatment, but current options don't always work well or last long. This trial exists to see if the new lab-grown blood vessel could be a better, safer choice than traditional surgery.
If you enroll, you will have surgery to receive either the lab-grown blood vessel or a traditional fistula, placed in your forearm or upper arm. You will then visit the research center regularly for the next 12 months to have the access checked, blood drawn, and overall health monitored. If your access is still working well at month 12, you may be asked to continue in a follow-up study for another year.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States